EVOFEM BIOSCIENC(EVFM) - 2025 Q4 - Annual Report

Product Launch and Market Opportunity - PHEXX, the first and only non-hormonal prescription contraceptive vaginal gel, was launched in the U.S. in September 2020, targeting approximately 15.9 million women who do not want to get pregnant and will not use hormonal contraceptives[21]. - The U.S. contraceptive market was valued at $8.8 billion in 2024 and is projected to reach approximately $12 billion by 2030, with a compound annual growth rate of 4.7%[34]. - An estimated 15.77 million women of reproductive age in the U.S. report using GLP-1 medications, creating a $904 million total addressable market for PHEXX among those also using oral contraceptives[42]. - Approximately 41.6% of all pregnancies in the U.S. are unintended, equating to about 2.3 million unintended pregnancies annually, highlighting the need for effective contraceptive options like PHEXX[44]. - The U.S. market presents the greatest opportunity for PHEXX and SOLOSEC, with a focus on approximately 15.9 million sexually active women using non-hormonal methods and 10.3 million using hormonal contraceptives[72]. - The U.S. market for contraceptives includes approximately 26.2 million women, with 15.9 million not seeking pregnancy and not using hormonal contraceptives, indicating a significant potential market for PHEXX[100]. Product Development and Manufacturing - The company aims to reduce the cost of goods sold (COGS) for PHEXX and SOLOSEC by approximately 55% to 60% by 2027 through new manufacturing contracts[32]. - The company is currently contracted with a leading U.S.-based gel manufacturer to produce PHEXX in compliance with cGMP regulations[130]. - The company reversed a contingent liability of $1.9 million related to the Rush Royalty after the USPTO denied the PTE application, impacting the cost of goods sold[140]. - Evofem relies on third parties for the production of PHEXX and SOLOSEC, which must comply with cGMP requirements[154]. Regulatory and Compliance - The FDA regulates the approval and marketing of drugs, requiring compliance with extensive regulations and potential penalties for non-compliance[150]. - The FDA may withdraw product approvals if compliance with regulatory standards is not maintained[155]. - Regulatory processes for obtaining approvals require substantial time and financial resources, impacting product development timelines[149]. - The FDA's regulations include monitoring and record-keeping activities post-approval, which are critical for maintaining product compliance[151]. - The company must comply with various laws and regulations, including the U.S. Foreign Corrupt Practices Act, which affects international operations[179]. Intellectual Property - The company owns or has exclusive licenses to approximately 35 issued patents and allowed applications related to PHEXX, with some patents expiring as late as 2033[145]. - The company has approximately 20 issued patents and allowed applications related to SOLOSEC, with additional trade secrets and know-how contributing to its competitive position[146]. - The intellectual property for PHEXX includes four U.S. patents, expected to protect the product until 2033[167]. - SOLOSEC is covered by eleven U.S. patents, with protection expected until 2041, and is also protected by NCE-GAIN Exclusivity until September 15, 2027[168]. Market Strategy and Partnerships - The company intends to leverage its U.S. sales force to acquire or in-license additional commercial products to diversify revenue streams and enhance offerings in women's health[33]. - The company has licensed commercial rights to PHEXX and SOLOSEC in the MENA region to Pharma 1, with plans for regulatory approval filings in the UAE in 2025[24]. - The company aims to establish regional and global partnerships for the commercialization of its products, enhancing market access and stakeholder value[128]. - The company is actively working with health plans and PBMs to improve formulary positioning for PHEXX and SOLOSEC, aiming for broader market access[82]. Patient Compliance and Treatment Efficacy - SOLOSEC demonstrated a cure rate of 92.2% for trichomoniasis in women during clinical trials, with male cure rates ranging from 91.7% to 100%[65]. - SOLOSEC's single-dose treatment approach addresses non-compliance issues seen with multi-day regimens, which affect up to 50% of BV patients[61]. - SOLOSEC's one-time oral dosing is expected to improve patient compliance and potentially reduce overall treatment costs[79]. - The company’s commercialization strategy includes leveraging telehealth platforms to provide direct access to PHEXX for women[71]. Financial and Market Access Challenges - Evofem's products depend on third-party payer coverage, with no uniform policy in the U.S. for drug reimbursement, leading to a time-consuming and costly coverage determination process[212]. - Legislative changes, including the ACA and the 2021 Consolidated Appropriations Act, have increased Medicaid rebates and imposed mandatory discounts for Medicare Part D beneficiaries, affecting the pharmaceutical industry[207]. - The Affordable Care Act mandates coverage for FDA-approved contraceptives, including PHEXX, with no out-of-pocket costs for women, effective January 1, 2023[90]. - Evofem anticipates continued pressure on pharmaceutical pricing due to increased emphasis on cost containment measures in the U.S.[215]. Employee and Organizational Structure - As of February 28, 2026, Evofem had a total of 29 full-time employees, with good relations maintained with employees and consultants[218]. - The company faces various risk factors that could materially affect its business, financial position, and trading price of securities[219].